This is Lundbeck

We are one of the only biopharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our science

Latest releases

18 October, 2023 Feature
Majority of Canadians on Public Drug Plans Now Eligible for Coverage of Vyepti® (eptinezumab) for the Prevention of Migraine
03 March, 2021 Feature
Health Canada Approves Otsuka and Lundbeck’s ABILIFY MAINTENA® (aripiprazole for prolonged release injectable suspension) Alternative Initiation Regimen
09 February, 2021 Feature
'Montréal's Top Employers' for 2021 Announced

See All News

Come join us in making a difference to patients worldwide.

Job opportunities

Through our sustainability strategy, we mitigate business risks, reduce negative impacts, and address societal challenges where possible.

Sustainability

A better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to supporting the person behind the disease.

Our focus

Our sustainability strategy

Through our sustainability strategy, we mitigate business risks, reduce negative impacts, and address societal challenges where possible. We remain committed to UN Global Compact Principles, and contribute to seven of the 17 UN Sustainable Development Goals.

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to developing new and better treatment options from innovations born in house or externally.